Transforming gene therapy through the discovery and detection of complex genetic changes
Direct, Definitive Genomics
single-cell innovative solutions for the discovery, evaluation, and characterization of gene editing, chromosomal rearrangements, and structural variations for cell and gene therapy scientists
Products
detect mutations, chromosomal rearrangements and structural variations with robust signals, and a genome wide perspective using dGH™ and Pinpoint FISH™ probes
Services
receive superior detection and quantifiable evaluation data using our robust dGH™ and Pinpoint FISH™ assay services and world class quality control
Applications
products and assay solutions for applications using cell and gene therapy, gene editing, oncology studies, and radiation biodosimetry
KromaTiD News
Company News + Press
- KromaTiD Announces Launch of Pinpoint FISH™ DNA Probes
- Just Up on the Blog! KromaTiD’s Dark Lab Files: The Great Race to Cure Cancer – CAR-T Segment
- Register for KromaTiD’s directional Genomic Hybridization™ Webinar Featured on GEN News April 27th
- Just Up on the Blog! KromaTiD’s Dark Lab Files: Cytogenetics a Little History Lesson
- KromaTiD Announces Launch of Cell Culture Services
- KromaTiD Announces EARLY ACCESS Launch of TP53/CEP17 Kit for Synthetic Oligonucleotide-Based FISH Assay
- KromaTiD Announces Launch of dGH SCREEN™
- Applied Spectral Imaging and KromaTiD announce strategic commercial partnership
- KromaTiD and dGH in-Site featured in Genetic Engineering & Biotechnology News
Videos, Presentations & Webinars
- KromaTiD Webinar CRISPR Off Target Gene Editing (GEN News)
- KromaTiD Presents at Next Gen Omics Boston
- KromaTiD’s Cell Culture Services Protocol
- Dr. Chris Tompkins and Erin Cross present webinar for the launch of dGH SCREEN™ for unbiased whole genome analysis of chromosomal structural rearrangements
- Dr. Lauren Kinner-Bibeau presents webinar on single-cell measurements of genomic inserts and transgenes
- KromaTiD presents at the 2020 virtual NextGen Omics Series
- KromaTiD CTO Dr. Chris Tompkins presents at the 2020 Cell & Gene Therapy Virtual Congress
Market News
- BMS Takes CAR-T Patent Case to Top Court in Bid to Revise $2.1B Verdict Against Gilead
- CDC Awards $215M in Cancer Research Funding
- Ocugen Announces New Gene Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition
- Bayer terminates CAR-T Collaboration with Atara Therapeutics
- Cytovia inks SPAC merger to get natural killer cells prospects into the clinic
- NKARTA touts a double dose of data for natural killer cell therapies
- UCSF Researchers Hope to Cure Sickle Cell Disease through CRISPR Gene Editing
- Mayo Researchers combine CAR-T and Oncolytic Virus in New Attack on Cancer
- Global Gene Therapy Market Expected to Grow to $5.02B by 2028, at 17%
- CRISPR Therapeutics, ViaCyte Dose First Patient with Cell Therapy for Type 1 Diabetes
- A New $28 Million Genomics National Agency will focus on making Australians live longer and better lives
- FDA Drafts Guidance on Genome Editing, CAR-T Cell Therapies